Immunomodulatory Peptides with High Binding Affinity for Class IIMHC Molecules for the Prevention of Graft-Versus-Host Disease

References

• Forman S. J., Blume K. G., Thomas D. E. Bone marrow transplantation. Oxford University Press, Oxford 1994
   Google Scholar
• Chao N. J., Schmidt G. M., Niland J. C., Amylon M. D., Dagis A. C., Long G. D., Nademanee A. P., Negrin R. S., O'Donnell M. R., Parker P. M., Smith E. P., Snyder D. S., Stein A. S., Wong R. M., Blume K. G., Forman S. F. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New England Journal of Medicine 1993; 329: 1225–1230
   PubMed Web of Science ®Google Scholar
• Chao N. J., Schlegel P. G. Prevention and treatment of graft-versus-host disease. Annals of the New York Academy of Sciences 1995, in press
   PubMed Web of Science ®Google Scholar
• Billingham R. The biology of graft-versus-host reaction. Harvey Lecture 1966; 21
   PubMedGoogle Scholar
• Sakamoto H., Michaelson J., Jones W. K., Bhan A. K., Abhyankar S., Silverstein M., Golan D. E., Burakoff S., Ferrara J. L. M. Lymphocytes with a CD4+CD8-CD3- phenotype are effectors of experimental graft-versus-host disease. Proc. Natl. Acad. Sci. USA 1991; 88: 10890–10894
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51–58
   PubMed Web of Science ®Google Scholar
• Hamilton B. L. L3T4-positive cells participate in the induction of graft-versus-host disease in response to minor histocompatibility antigens. J. Immunol. 1987; 139: 2511–2515
   PubMed Web of Science ®Google Scholar
• Korngold R., Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J. Exp. Med. 1987; 165: 1552–1564
   PubMed Web of Science ®Google Scholar
• Parkman R. Clonal analysis of murine graft-versus-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J. Immunol. 1986; 136: 3543–3548
   PubMed Web of Science ®Google Scholar
• Korngold R. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant 1992; 9: 355–364
   PubMed Web of Science ®Google Scholar
• Korngold R., Sprent J. T-cell subsets in graft-vs.-host disease. Graft-vs.-Host Disease. Immunology, Pathophysiology, and Treatment, S. J. Burakoff, H. J. Deeg, J. Ferrara, K. Atkinson. Marcel Dekker, New York 1990; 31–49
   Google Scholar
• Shenoy S., Mohanakumar T. MHC class II in β2-microglobulin deficient mice following bone marrow transplantation. The 9th International Congress of Immunology. 1995; A428, Graft versus host disease is mediated through
   Google Scholar
• Perreault C., DÉCary F., Brochu S., Gyger M., BÉLanger R., Roy D. Minor histocompatibility antigens. Blood 1990; 76: 1269–1280
   PubMed Web of Science ®Google Scholar
• Griem P., Wallny H. J., Falk K., RÖTzschke O., Arnold B., SchÖNrich G., HÄMmerling G., Rammensee H. G. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 1991; 65: 633–640
   PubMed Web of Science ®Google Scholar
• Den Haan J. M., Sherman N. E., Blokland E., Huczko E., Koning F., Drijfhout J. W., Skipper J., Shabanowitz J., Hunt D. F., Engelhard V. H., Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476–80
   PubMed Web of Science ®Google Scholar
• Wang W., Meadows L. R., Den Haan J. M. M., Sherman N. E., Chen Y., Blokland E., Shabanowitz J., Agulnik A. I., Hendrickson R. C., Bishop C. E., Hunt D. F., Goulmy E., Engelhard V. H. Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588–1590
   PubMed Web of Science ®Google Scholar
• Speiser D. E., ZÜRcher T., Ramseier H., Hengartner H., Staeheli P., Haller O., Zinkernagel R. M. Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen. Proc. Natl. Acad. Sci. USA 1990; 87: 2021–2025
   PubMed Web of Science ®Google Scholar
• Wallny P. J., Rammensee H. G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990; 343: 275–278
   PubMed Web of Science ®Google Scholar
• Roopenian D. C., Christianson G. J., Davis A. P., Zuberi A. R., Mobraaten L. E. The genetic origin of minor histocompatibility antigens. Immunogenetics 1993; 38: 131–140
   PubMed Web of Science ®Google Scholar
• Hunt D. F., Michel H., Dickinson T. A., Shabanowitz J., Cox A. L., Sakaguchi K., Appella E., Grey H. M., Sette A. Peptides presented to the immune system by the murine class II MHC molecule I-Ad. Science 1992; 256: 1817–1820
   PubMed Web of Science ®Google Scholar
• Nestel F. P., Price K. S., Seemayer T. A., Lapp W. S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 1992; 175: 405–13
   PubMed Web of Science ®Google Scholar
• Piguet P. F., Grau G. E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 1987; 166: 1280–1289
   PubMed Web of Science ®Google Scholar
• McCarthy P. L., Jr., Abhyankar S., Neben S., Newman G., Sieff C., Thompson R. C., Burakoff S. J., Ferrara J. L. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915–1918
   PubMed Web of Science ®Google Scholar
• Rus V., Svetic A., Nguyen P., Gause W. C., Via C. S. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J. Immunol. 1995; 155: 2396–2406
   PubMed Web of Science ®Google Scholar
• Schlegel P. G., Aharoni R., Smilek D. E., Fernandez L. P., McDevitt H. O., Tran N., Vaysburd M., Chao N. J. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84: 2802–2810
   PubMed Web of Science ®Google Scholar
• Schlegel P. G., Aharoni R., Vaysburd M., Tran N., McDevitt H. O., Chao N. J. Inhibition of secondary MLR and prevention of murine graft-versus-host disease across minor histocompatibility barriers by peptides with high binding affinity for class II MHC molecules. FASEB 1994; 8: A478
   Web of Science ®Google Scholar
• Chao N. J. Graft-versus-host disease. Curr. Opin. Immunol. 1992; 4: 571–576
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Taylor P. A., Panoskaltsis-Mortari A., Gray G. S., Vallera D. A. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995; 85: 2607–2618
   PubMed Web of Science ®Google Scholar
• Wallace P. M., Johnson J. S., Macmaster J. F., Kennedy K. A., Gladstone P., Linsley P. S. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58: 602–610
   PubMed Web of Science ®Google Scholar
• Schlegel P. G., Vaysburd M., Chen Y., Butcher E., Chao N. J. Inhibition of T cell costimulation mediated by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J. Immunol. 1995; 155: 3856–3865
   PubMed Web of Science ®Google Scholar
• Clayberger C., Krensky A. M. Immunosuppressive peptides corresponding to MHC class I sequences. Curr. Opin. Immunol. 1995, in press
   PubMed Web of Science ®Google Scholar
• Jameson B. A., McDonnell J. M., Marini J. C., Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 1994; 368: 744–746
   PubMed Web of Science ®Google Scholar
• Townsend R. M., Marini J. C., Jameson B. A., Korngold R. Efficacy of a CD4 peptide analog to treat GVHD during allogeneic bone marrow transplantation. The 9th International Congress of Immunology. 1995; A430
   Google Scholar
• Brown J. H., Jardetzky T. S., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DRI. Nature 1993; 364: 33–39
   PubMed Web of Science ®Google Scholar
• Rudesnsly A. Y., Preston-Hurlburt P., Al-Ramadi B. K., Rothbard J., Janeway C. A. Truncation variants of peptides isolated from class II molecules suggest sequence motifs. Nature 1992; 359: 429–431
   PubMed Web of Science ®Google Scholar
• Babbitt B. P., Matsueda G., Haber E., Unanue E. R., Allen P. M. Antigenic competition at the level of peptide-Ia binding. Proc. Natl. Acad. Sci. USA 1986; 83: 4509–4513
   PubMed Web of Science ®Google Scholar
• Wraith D. C., Smilek D. E., Mitchell D. J., Steinman L., McDevitt H. O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell 1989; 59: 247–255
   PubMed Web of Science ®Google Scholar
• Gautam A. M., Pearson C. I., Smilek D. E., Steinman L., McDevitt H. O. A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J. Exp. Med. 1992; 176: 605–609
   PubMed Web of Science ®Google Scholar
• Smilek D. E., Lock C. B., McDevitt H. O. Antigen recognition and peptide-mediated immunotherapy to autoimmune disease. Immunol. Rev. 1990; 118: 37–71
   PubMed Web of Science ®Google Scholar
• Lamont A. G., Sette A., Fujinami R., Colon S. M., Miles C., Grey H. M. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for I-As molecules. J. Immunol. 1990; 145: 1687–1693
   PubMed Web of Science ®Google Scholar
• Fairchild P. J., Wildgoose R., Atherton E., Webb S., Wraith D. C. An autoantigenic T cell epitope forms unstable complexes with class II MHC: Anovel route for escape from tolerance induction. Int. Immunol. 1993; 5: 1151–58
   PubMed Web of Science ®Google Scholar
• Ishioka G. Y., Adorini L., Guery J. G., Gaeta F. C. A., Lafond R., Alexander J., Powell M. F., Sette A., Grey H. M. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. J. Immunol. 1994; 152: 4310–4319
   PubMed Web of Science ®Google Scholar
• Samson M. F., Smilek D. E. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol. 1995; 155: 2737–2746
   PubMed Web of Science ®Google Scholar
• Gaur A., Wiers B., Liu A., Rothbard J., Fathman C. G. Amelioration autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491–1494
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J., Evavold B. D., Allen P. M. Induction of T cell anergy by altered T cell receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156–159
   PubMed Web of Science ®Google Scholar
• Evavold B. D., Allen P. M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308–1310
   PubMed Web of Science ®Google Scholar
• Guery J. C., Adorini L. Selective immunosuppression of class II-restricted T cells by MHC class II-binding peptides. Crit. Rev. Immunol. 1993; 13: 195–206
   PubMed Web of Science ®Google Scholar